Trial Profile
A Phase 2, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Ataluren (Primary)
- Indications Aniridia
- Focus Proof of concept; Therapeutic Use
- Acronyms STAR
- Sponsors PTC Therapeutics
- 04 Mar 2021 Status changed from active, no longer recruiting to completed.
- 08 Jan 2021 Planned End Date changed from 21 Feb 2022 to 29 Jan 2021.
- 08 Jan 2021 Planned primary completion date changed from 21 Feb 2022 to 29 Jan 2021.